Investor Presentation H1 2023
24.
Investor presentation
First six months of 2023
Novo NordiskⓇ
Novo Nordisk's opportunity is in the large unmet needs across all
therapy areas in scope.
Diabetes care
537m
people with
diabetes¹
~15%
of people in
good control²
Rare disease
Haemophilia
0.6m
-35%
people with
haemophilia4
of people being treated
Novo
Nordisk
Way
Driving change to
defeat diabetes
and other serious
chronic diseases
ustainable business
>764m
people with
obesity³
16%
of global deaths
caused by
ASCVD5
>30m
people
affected by
HFPEF6
Obesity care
~2%
of people in medically
treated
Other serious
chronic diseases
>25m
people
affected by
NASH7
>70m
people
affected by AD³
1 International Diabetes Federation: Diabetes Atlas 10th edition, 2021; 2Real-world studies indicate between 30-55% of patients reach HbA1c target <7% .e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/, taking 42.5% in good control of treated people; 3 World
Diabetes Atlas 2022; 4 WFH annual survey 2020 (120 of 147 countries responded): Prevalence by calculating expected number of patients using 20.9 per 100.000 in haemophilia Identified patients as proxy for receiving some sort of treatment; 5 "The top 10
causes of death", WHO, 9 December 2020 (ASCVD denoted as ischaemic heart disease); "Groenewegen A et al. Eur J Heart Fail 2020;22:1342-13561; Gurwitz JH et al. Am J Med 2013;126:393-400; 7Estes C, Modeling the epidemic of non-alcoholic fatty liver disease
demonstrates an exponential increase in burden of disease, Hepatology, 2018; 8The World Alzheimer Report 2015, The Global Impact of Dementia, Alzheimer's Disease International (ADI), London.View entire presentation